InvestorsHub Logo
Followers 826
Posts 119448
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Monday, 02/08/2021 8:06:46 PM

Monday, February 08, 2021 8:06:46 PM

Post# of 1162
Opdivo monotherapy shows statsig-superior DFS to placebo in adjuvant MIUC*:

https://finance.yahoo.com/news/adjuvant-treatment-opdivo-nivolumab-demonstrates-220000022.html

The CHECKMATE-274 study is the first phase-3 immunotherapy trial to show a clinical benefit in this setting. The HR for DFS was 0.70 in the overall trial and 0.53 in the subgroup with PD-L1>=1% (p<0.001 for both results).

*Muscle-Invasive Urothelial Carcinoma.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News